Tafamidis (Vyndaqel; Vyndamax): Why Two Products?

Our website now hosts a free article about tafamidis, a new drug in the US approved for treatment of adults with transthyretin-mediated amyloid cardiomyopathy, a progressive, life-threatening, under-diagnosed disease often referred to by its acronym (ATTR-CM). The drug was approved in 2 formulations with different brand names and different doses, both manufactured by Pfizer.

Vyndaqel (tafamidis meglumine) has been approved in Europe since 2011 for treatment of transthyretin amyloid polyneuropathy (ATTR-PN) and is now approved for that indication in 40 countries. It is formulated as 20-mg capsules; the dose recommended for treatment of ATTR-CM is 80 mg once daily.

Vyndamax (tafamidis) is brand new. It is formulated as 61-mg capsules; the recommended dose is 61 mg once daily. The package insert, which the two drugs share, states that no clinically significant pharmacokinetic differences in peak blood levels (Cmax) or concentration/time curve (AUC) were observed between 4 capsules of Vyndaqel and a single capsule of Vyndamax.

The pivotal clinical trial randomized patients to 20- or 80-mg doses of Vyndaqel or placebo. Patients taking either dose of the active drug were pooled and compared to the patients on placebo; all-cause mortality and cardiovascular hospitalizations were significantly less frequent with the drug. Efficacy was the same with either the 20- or the 80-mg dose (MS Maurer et al. Tafamidis treatment for patients with transthyretin cardiomyopathy. N Engl J Med 2018; 379:1007).

According to a company statement, Vyndamax was developed to give patients the convenience of taking one rather than four capsules once a day. Both Vyndaqel and Vyndamax have a wholesale acquisition cost of $18,750 a month. Since 20 mg of Vyndaqel has been as effective as 80 mg, the cost could be cut by 75% by taking the lower dose, as long as Vyndaqel is not phased out to protect the higher price.

Enter your email address to follow this blog and receive notifications of new posts by email.

Leave a Reply:

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s